Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.
In China, researchers investigate the sustained virologic response and safety profile of coblopasvir plus sofosbuvir taken once daily for 12 weeks among patients with HCV genotypes 1, 2, 3, or 6 infections, including individuals with compensated cirrhosis.
The Public Health England Hepatitis C Virus Resistance Group recommended testing resistance for treatment of the hepatitis C virus by using a genotypic testing method of either the Sanger sequencing or next-generation sequencing methods.
Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.
As emergency departments (EDs) are critical settings for hepatitis C care in the United States, investigators evaluated trends and characteristics of hepatitis C-associated ED visits from 2006 to 2014.
In a small patient cohort, researchers found that heart transplantation from donors who were hepatitis C virus-positive to recipients without the virus were successful.
The prevalence of hepatitis C virus in the US population born after 1985 and Mexican Americans is suggested by researchers to be due to the opioid epidemic.
Using data from an Egyptian cohort, investigators sought to determine the safety and efficacy of adding epigallocatechin gallate to sofosbuvir plus daclatasvir with or without ribavirin to treat patients with chronic hepatitis C virus.
In Wisconsin, researchers found data that showed people who inject drugs are susceptible to hepatitis A virus infection, and those aged over 35 are susceptible to hepatitis B infection.
The study researchers concluded that different DAA therapies may be safely used with high SVR12 rates in patients with HCV and GFR less than 30 ml/min, except for ribavirin due to poor tolerability.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
As direct-acting antiviral (DAA) treatment can lead to HBV re-activation, testing for HBV DNA along with anti-HBc antibodies in men who have sex with men and people who use drugs co-infected with hepatitis C virus is warranted prior to DAA-treatment.
Researchers focus on differences and parallels among HIV, HCV and HBV with an emphasis on virologic and therapeutic issues, and prospects for the future of HBV.
According to a recently published study, a high level of hepatitis B core-related antigen is a complementary risk factor for hepatocellular carcinoma development.
Investigators assessed the diagnostic performance of AST to Platelet Ratio Index and Fibrosis-4 scores compared with transient elastography evaluation of liver stiffness to detect significant fibrosis or cirrhosis.
Researchers suggest that novel biologicals should be explored as a treatment alternative to hepatitis vaccination for patients who are being treated with immunosuppressive drugs.
Adult heart transplants from hepatitis C virus-positive (HCV+) donors appear safe, with no increased risk for adverse effects on one-year survival.
Researchers found data that showed schistosomiasis does not escalate liver damage in patients who are infected with the hepatitis B virus.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.
Investigators found data that showed patients with hepatitis C virus infection who had a sustained viral response to treatment with interferon had less incidence of extrahepatic manifestations.